Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RPH-002 vs Erbitux in Advanced Head and Neck Squamous Cell Carcinoma
NCT07435324Phase 3Completed
- Sponsor
- R-Pharm
- Start
- Aug 2024
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of cetuximab biosimilar RPH-002 in head and neck squamous cell carcinoma (HNSCC), sponsored by R-Pharm. Started Aug 2024; status: completed.
02
Drugs
cetuximab biosimilar RPH-002
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07435324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07435324.